Sign in
Markets
Screener
Signals
Library
API
Help
Chat
Stories
CARMAT's Advancements in Artificial Heart Technology
Share
BiVACOR Appoints New Chairman
BiVACOR Welcomes New CEO and FDA Approva...
CARMAT's 2024 Financial Calendar and Hea...
AI-Powered Raspberry Pi Stethoscope Inno...
Overview
API
CARMAT, a company specializing in the Aeson® artificial heart, has achieved a milestone of 50 implants and presents its development prospects. The company has seen significant advancements in sales and safety profile, aiming to provide a therapeutic alternative for patients with advanced heart failure.
Ask a question
How does the software enhancement for Aeson® contribute to its safety profile and potential commercial success?
How might the advancements in Aeson® technology impact the treatment of heart failure?
What challenges might the expansion of therapy on a large scale present for CARMAT?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Coverage